Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zogenix has entered into a license agreement to grant exclusive rights in the EU to Desitin Pharmaceuticals, to develop and commercialize Zogenix's late stage, single use, needle-free product candidate for migraine headache, sumatriptan DosePro.
Subscribe to our email newsletter
Under the terms of the agreement, Desitin will oversee, and be responsible for the expenses related to, all clinical development, regulatory approvals and commercialization efforts required to market and sell sumatriptan DosePro across Europe. Zogenix will be responsible for the manufacture and supply of commercial product, and will receive a transfer price payment on manufactured product and royalty payments based on sales of the product upon commercialization. Zogenix retains full commercial rights to sumatriptan DosePro in the US, Canada, Asia and certain other countries.
Roger Hawley, CEO of Zogenix, said: “This license agreement expands the potential reach for sumatriptan DosePro beyond the US, where, subject to regulatory approval, Zogenix is preparing to commercialize sumatriptan DosePro ourselves. We look forward to seeing sumatriptan DosePro advance through these steps and launch in the European marketplace.”